

## [Omeprazole](#)

Essential medicine status

Section:

[17. Gastrointestinal medicines 17.1. Antiulcer medicines](#)

ATC codes: [A02BC01](#)

EMLc

Indication

Gastro-oesophageal reflux disease ICD11 code: [DA22.Z](#)

INN

Omeprazole

Medicine type

Chemical agent

List type

Core

Formulations

**Oral > Liquid:** 1 mg per mL powder for oral liquid ; 4 mg per mL powder for oral liquid

**Oral > Solid > dosage form:** 10 mg ; 20 mg ; 40 mg

EML status history

First added in 2009 ([TRS 958](#))

Changed in 2021 ([TRS 1035](#))

Changed in 2025 ([TRS 1064](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

Medicines within the same pharmacological class can be used

Therapeutic alternatives limitations

Therapeutic alternatives are medicines in the 4th level ATC chemical subgroup A02BC Proton pump inhibitors (excluding combinations)

Therapeutic alternatives limitations for EMLc

Therapeutic alternatives are medicines in the 4th level ATC chemical subgroup A02BC Proton pump inhibitors (excluding combinations)

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Omeprazole](#)

DrugBank

[Omeprazole](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the deletion of omeprazole powder for oral liquid 20 mg and 40 mg sachets; - the addition of omeprazole powder for oral liquid 1 mg/mL and 4 mg/mL.